September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Controlled vancomycin release from biodegradable nanoparticles
Author Affiliations & Notes
  • Emily Dosmar
    Biomedical Engineering , Illinois Institute of Technology, Chicago, Illinois, United States
  • Jennifer J Kang-Mieler
    Biomedical Engineering , Illinois Institute of Technology, Chicago, Illinois, United States
  • William F Mieler
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Emily Dosmar, None; Jennifer Kang-Mieler, None; William Mieler, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3986. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emily Dosmar, Jennifer J Kang-Mieler, William F Mieler; Controlled vancomycin release from biodegradable nanoparticles. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3986.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The purpose of this study was to investigate the use of poly (lactic-co-glycolic acid) (PLGA) based nanoparticles to deliver prophylactic vancomycin (VAN) for two weeks following ocular surgery.

Methods : VAN was encapsulated in hydrolytically degradable acid terminated PLGA based nanoparticles. Nanoparticles were synthesized using a double emulsion processes. Lactide:glycolide (PL:GA) ratios and molecular weight were varied to assess the release characteristics of the nanoparticles. VAN release profiles were conducted at 37°C; at predetermined intervals, samples were analyzed via light spectroscopy using a NanoDrop™ 2000/2000C (280nm, E1% 40) to quantify VAN concentration.

Results : Nanoparticle encapsulation efficiency was 26 ± 5% for all protocols. PL:GA ratio and molecular weight (MW) did not appear to affect the initial burst of drug (drug release within the first 24 hours) from the nanoparticles (207 ± 3 mg/ml and 204 ± 3 mg/ml for PLGA 75:25; MW 4,000-15,000 and PLGA 50:50; MW 7,000-17,000, respectively). Nanoparticles synthesized from a combination of two different PL:GA ratios (equal parts 75:25 and 50:50) demonstrated a higher initial burst of drug (605 ± 1 mg/ml). Following the initial burst, nanoparticles released a steady level of 8 ± 5 mg/ml, 11 ± 5 mg/ml, and 3 ± 3 mg/ml for PLGA 75:25, PLGA 50:50, and 50% combined nanoparticles, respectively. PL:GA ratio and molecular weight did not demonstrate a strong influence on early release characteristics. The combined polymer system released the smallest amount following a large initial burst.

Conclusions : This study demonstrated that while a combined polymer system does not improve release characteristics, nanoparticles fabricated from PLGA 75:25 or PLGA 50:50 may have promise for application as a vehicle for short term, prophylactic antibiotic ocular drug delivery.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.